Michael J. Morris
Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.
Overview
Michael J. Morris is Prostate Cancer Section Head on the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is a medical oncologist known as principal investigator of the VISION trial, which made lutetium-177 PSMA radioligand therapy a standard prostate cancer treatment, and co-led PSMAfore and PSMA PET studies. His selected papers report lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and the PSMAfore comparison against a change of androgen receptor pathway inhibitor in taxane-naive patients. He chaired the Alliance genitourinary committee and focuses on radioligand therapy and imaging biomarkers.
For men who still have a working hormone treatment option but whose cancer is progressing, offering the PSMA radioligand therapy sooner - before chemotherapy - delayed disease progression, though it did not clearly extend how long men lived once the very high rate of patients switching over is accounted for.
For men whose prostate cancer has grown after chemotherapy, a PSMA-targeted radioactive treatment worked at least as well as, and was gentler than, the chemotherapy drug it replaced - provided a PET scan first confirms the cancer takes up the PSMA tracer.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Similar pages
not linked directly; found by shared links- PersonA. Oliver Sartor
Shares Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617, PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, PSMAfore, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer.
- PersonLouise Emmett
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- PersonKen Herrmann
Shares PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, VISION, PSMA.
- PersonMichael Hofman
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, Lutetium-177 vipivotide tetraxetan.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- TermSalivary gland toxicity (xerostomia) from PSMA radioligand therapy
Shares PSMAfore, VISION, PSMA, Lutetium-177 vipivotide tetraxetan.
- AgentLocametz (kit for Ga-68 gozetotide)
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, VISION, PSMA, Lutetium-177 vipivotide tetraxetan.
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).